All In Biotech

NDA 021585 · Reckitt Benckiser

Mucinex D

Guaifenesin, Pseudoephedrine Hydrochloride · Oral · Expectorant

Last checked: Nov 19, 2026Latest source record: Jul 8, 2024 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

2004

Jun 22, 2004

Approved uses

1

Original approval plus efficacy supplements

Registered trials

147

31 Phase 3, 6 recruiting

FAERS reports

1,816

694 serious, 58 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

What it is approved for

From the label in effect May 27, 2026.

Uses helps loosen phlegm (mucus) and thin bronchial secretions to rid the bronchial passageways of bothersome mucus and make coughs more productive temporarily relieves nasal congestion due to: common cold hay fever upper respiratory allergies temporarily restores freer breathing through the nose promotes nasal and/or sinus drainage temporarily relieves sinus congestion and pressure

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

2 products under this application
  • MUCINEX D · GUAIFENESIN 600MG; PSEUDOEPHEDRINE HYDROCHLORIDE 60MG · TABLET, EXTENDED RELEASE, ORAL · Over-the-counter
  • MUCINEX D · GUAIFENESIN 1.2GM; PSEUDOEPHEDRINE HYDROCHLORIDE 120MG · TABLET, EXTENDED RELEASE, ORAL · Over-the-counter

Clinical trials

Interventional ClinicalTrials.gov studies with "Guaifenesin" as an intervention, any sponsor and status, largest first.

All 147 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • drug ineffective147
  • insomnia146
  • dizziness129
  • headache112
  • nausea108
  • fatigue105
  • dyspnoea85
  • accidental overdose76
  • cough72
  • sinusitis71
  • diarrhoea69
  • pain68

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
20052
20066
20073
20088
200920
201058
201134
201252
201378
201459
2015132
2016227
2017223
2018175
2019147
2020151
202157
202296
202396
202487
202579
202626

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Not found under this brand name in Medicare's Part D or Part B Spending by Drug data. CMS lists some drugs under the generic name only.

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 60 on PubMed

Sponsor: Reckitt Benckiser

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.